VELOCITY: An Anthrax Vaccine Clinical Study

Anthrax

Evaluation of the SRI B. Anthracis Lethal Factor Diagnostic System Anthrax AV7909 Liquid vs Lyophilized Febrile Whole Blood Specimen Collection and Testing Ph1 Study of Valortim and Doxycycline in Humans Ph1 Study of Valortim and Ciprofloxacin in Humans Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9) A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects Trial of rPA-102 Vaccine in Healthy Adult Volunteers Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults Ciprofloxacin BioThrax Co-Administration Study Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study A Study of Anthrax Vaccines Px563L and RPA563 in Healthy Adult Subjects PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine Efficacy and Safety of Anthrax Vaccine, GC1109 Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults Glyburide Advantage in Malignant Edema and Stroke – Remedy Pharmaceuticals Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV) A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults Anthrax Vaccine Clinical Trials Anthrax-rPA: Safety, Tolerability, Immunogenicity BARDA Securing Anthrax Immunity For the Elderly An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels Evaluation of the Clinical Specificity of the Active Anthrax Detect™ Plus (AAD Plus) Lateral Flow Immunoassay (LFI) VELOCITY: An Anthrax Vaccine Clinical Study Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax